首页> 美国卫生研究院文献>Journal of the Boston Society of Medical Sciences >Reactivity of monoclonal anti-human pancreatic carcinoma antibodies AR2-20 and AR1-28 with tumors of nonpancreatic origin.
【2h】

Reactivity of monoclonal anti-human pancreatic carcinoma antibodies AR2-20 and AR1-28 with tumors of nonpancreatic origin.

机译:单克隆抗人胰腺癌抗体AR2-20和AR1-28与非胰腺源性肿瘤的反应性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The reactivity of two IgG1 murine monoclonal antibodies, AR2-20 and AR1-28 directed against the RWP-1 and RWP-2 human pancreatic cell lines was evaluated with paraffin sections of nonpancreatic human carcinomas. These monoclonal antibodies, which are directed against a 200-kd glycoprotein, and which did not stain normal tissues, were both reactive with 6 of 116 neoplasms (6 of 103 carcinomas) by indirect immunofluorescent histochemistry. This contrasts with the positive incidence of staining obtained with 29 of 34 human pancreatic adenocarcinomas. The two antibodies have specificities different from those previously described that reacted with pancreatic neoplasms. The significance of these findings is discussed with respect to the use of these antibodies in a diagnostic panel.
机译:用非胰腺人癌的石蜡切片评估了两种针对RWP-1和RWP-2人胰腺细胞株的IgG1鼠单克隆抗体AR2-20和AR1-28的反应性。这些针对200 kd糖蛋白的单克隆抗体,并且不染色正常组织,都通过间接免疫荧光组织化学与116个肿瘤中的6个(103个癌中的6个)反应。这与34种人胰腺腺癌中29种获得的染色阳性率相反。这两种抗体的特异性不同于先前描述的与胰腺肿瘤反应的特异性。关于这些抗体在诊断小组中的用途,讨论了这些发现的意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号